Regeneron has said it has begun clinical trials of its antibody cocktail therapy for COVID-19, as pharma companies continue their search for treatments as the pandemic continues to cause havoc ...

Hard on the heels of Regeneron moving its COVID-19 antibody cocktail into late-stage testing, the US government has agreed a deal to ramp up manufacturing – and claim the first doses to be made.

The team created a novel tick antigen library housing over 3,000 different proteins, testing each to create a target cocktail ...

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

The world’s foremost influenza experts know remarkably little; they have not even known that flu was a virus for very long. To inform us about its evolutionary history, its human history and what it ...

A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

A team of scientists has uncovered the remarkable potential of a human antibody, mAb 3A6, in fighting Ebola virus infections.

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of 113 healthcare workers in Catalonia who were followed during three years.